A wide range of symptoms and severity makes the evaluation of Covid-19
vaccines tricky. The U.S. Food and Drug Administration has said that
to be approved, vaccines should cut the number of symptomatic cases by
half. Yet documents released by the drugmakers show each has its own
approach to defining which symptoms count, and when to count them.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/pfizer-is-on-track-to-be-first-to-find-out-if-its-covid-vaccine-works/articleshow/78269671.cms
No comments:
Post a Comment